Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

Summary

Ascletis initiated a Phase 1 trial in the U.S. for ASC36, an oral amylin receptor peptide agonist for obesity treatment, which demonstrated 6-8% oral bioavailability in preclinical studies using the company's POTENT technology.